☰

Matthew G. Bursavich, Ph.D. - Publications

Affiliations: 
2002 University of Wisconsin, Madison, Madison, WI 
Area:
aspartic protease
Tree Info Similar researchers PubMed Report error

22 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Bursavich MG, Harrison BA, Acharya R, Costa DE, Freeman EA, Hodgdon HE, Hrdlicka LA, Jin H, Kapadnis S, Moffit JS, Murphy DA, Nolan S, Patzke H, Tang C, Wen M, et al. Design, Synthesis and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease. Journal of Medicinal Chemistry. PMID 28230986 DOI: 10.1021/Acs.Jmedchem.6B01620  0.379
2016 Blain JF, Bursavich MG, Freeman EA, Hrdlicka LA, Hodgdon HE, Chen T, Costa DE, Harrison BA, Kapadnis S, Murphy DA, Nolan S, Tu Z, Tang C, Burnett DA, Patzke H, et al. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. Alzheimer's Research & Therapy. 8: 34. PMID 27572246 DOI: 10.1186/S13195-016-0199-5  0.303
2016 Bursavich MG, Harrison BA, Blain JF. Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon? Journal of Medicinal Chemistry. PMID 27007185 DOI: 10.1021/Acs.Jmedchem.5B01960  0.302
2013 Bursavich MG, Dastrup D, Shenderovich M, Yager KM, Cimbora DM, Williams B, Kumar DV. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads. Bioorganic & Medicinal Chemistry Letters. 23: 6829-33. PMID 24183538 DOI: 10.1016/J.Bmcl.2013.10.008  0.475
2012 Vijay Kumar D, Hoarau C, Bursavich M, Slattum P, Gerrish D, Yager K, Saunders M, Shenderovich M, Roth BL, McKinnon R, Chan A, Cimbora DM, Bradford C, Reeves L, Patton S, et al. Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorganic & Medicinal Chemistry Letters. 22: 4377-85. PMID 22632936 DOI: 10.1016/J.Bmcl.2012.04.131  0.353
2010 Cole DC, Olland AM, Jacob J, Brooks J, Bursavich MG, Czerwinski R, DeClercq C, Johnson M, Joseph-McCarthy D, Ellingboe JW, Lin L, Nowak P, Presman E, Strand J, Tam A, et al. Identification and characterization of acidic mammalian chitinase inhibitors. Journal of Medicinal Chemistry. 53: 6122-8. PMID 20666458 DOI: 10.1021/Jm100533P  0.411
2010 Bursavich MG, Brooijmans N, Feldberg L, Hollander I, Kim S, Lombardi S, Park K, Mallon R, Gilbert AM. Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies. Bioorganic & Medicinal Chemistry Letters. 20: 2586-90. PMID 20303263 DOI: 10.1016/J.Bmcl.2010.02.082  0.425
2010 Tsou HR, MacEwan G, Birnberg G, Grosu G, Bursavich MG, Bard J, Brooijmans N, Toral-Barza L, Hollander I, Mansour TS, Ayral-Kaloustian S, Yu K. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorganic & Medicinal Chemistry Letters. 20: 2321-5. PMID 20188552 DOI: 10.1016/J.Bmcl.2010.01.135  0.429
2010 Bursavich MG, Parker DP, Willardsen JA, Gao ZH, Davis T, Ostanin K, Robinson R, Peterson A, Cimbora DM, Zhu JF, Richards B. 2-Anilino-4-aryl-1,3-thiazole inhibitors of valosin-containing protein (VCP or p97). Bioorganic & Medicinal Chemistry Letters. 20: 1677-9. PMID 20137940 DOI: 10.1016/J.Bmcl.2010.01.058  0.436
2010 Gilbert AM, Nowak P, Brooijmans N, Bursavich MG, Dehnhardt C, Santos ED, Feldberg LR, Hollander I, Kim S, Lombardi S, Park K, Venkatesan AM, Mallon R. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorganic & Medicinal Chemistry Letters. 20: 636-9. PMID 19969455 DOI: 10.1016/J.Bmcl.2009.11.051  0.403
2010 Venkatesan AM, Dehnhardt CM, Chen Z, Santos ED, Dos Santos O, Bursavich M, Gilbert AM, Ellingboe JW, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I, Feldberg L, Lucas J, et al. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Bioorganic & Medicinal Chemistry Letters. 20: 653-6. PMID 19954970 DOI: 10.1016/J.Bmcl.2009.11.057  0.415
2009 Nowak P, Cole DC, Brooijmans N, Bursavich MG, Curran KJ, Ellingboe JW, Gibbons JJ, Hollander I, Hu Y, Kaplan J, Malwitz DJ, Toral-Barza L, Verheijen JC, Zask A, Zhang WG, et al. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. Journal of Medicinal Chemistry. 52: 7081-9. PMID 19848404 DOI: 10.1021/Jm9012642  0.442
2008 Gilbert AM, Bursavich MG, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA. N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorganic & Medicinal Chemistry Letters. 18: 6454-7. PMID 18974001 DOI: 10.1016/J.Bmcl.2008.10.065  0.436
2007 Bursavich MG, Gilbert AM, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA. 5'-Phenyl-3'H-spiro[indoline-3,2'-[1,3,4]thiadiazol]-2-one inhibitors of ADAMTS-5 (aggrecanase-2). Bioorganic & Medicinal Chemistry Letters. 17: 5630-3. PMID 17804234 DOI: 10.1016/J.Bmcl.2007.07.048  0.426
2007 Gilbert AM, Bursavich MG, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA. 5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5. Bioorganic & Medicinal Chemistry Letters. 17: 1189-92. PMID 17210252 DOI: 10.1016/J.Bmcl.2006.12.020  0.437
2007 Bursavich MG, Gilbert AM, Lombardi S, Georgiadis KE, Reifenberg E, Flannery CR, Morris EA. Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorganic & Medicinal Chemistry Letters. 17: 1185-8. PMID 17210251 DOI: 10.1016/J.Bmcl.2006.12.027  0.471
2005 Bursavich MG, Lombardi S, Gilbert AM. Expedient parallel synthesis of 2-amino-4-heteroarylpyrimidines. Organic Letters. 7: 4113-6. PMID 16146365 DOI: 10.1002/CHIN.200604148  0.383
2002 Rich DH, Bursavich MG, Estiarte MA. Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations. Biopolymers. 66: 115-25. PMID 12325161 DOI: 10.1002/Bip.10231  0.565
2002 Bursavich MG, Rich DH. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. Journal of Medicinal Chemistry. 45: 541-58. PMID 11806706 DOI: 10.1021/Jm010425B  0.583
2001 Travins JM, Bursavich MG, Veber DF, Rich DH. Aspartic protease inhibitors: expedient synthesis of 2-substituted statines. Organic Letters. 3: 2725-8. PMID 11506619 DOI: 10.1021/Ol016331D  0.576
2001 Bursavich MG, Rich DH. Solid-phase synthesis of aspartic peptidase inhibitors: 3-alkoxy-4-aryl piperidines. Organic Letters. 3: 2625-8. PMID 11506594 DOI: 10.1021/Ol016280K  0.587
2001 Bursavich MG, West CW, Rich DH. From peptides to non-peptide peptidomimetics: design and synthesis of new piperidine inhibitors of aspartic peptidases. Organic Letters. 3: 2317-20. PMID 11463305 DOI: 10.1021/Ol016092U  0.619
Show low-probability matches.